Identifying risk factors for thrombosis in immune-mediated hemolytic anemia in dogs
Dogs with Immune-Mediated Hemolytic Anemia (IMHA) are at high risk for developing blood clots. This likely contributes to the high mortality rates reported with this disease. There are likely multiple causes for this tendency, but new evidence suggests that neutrophil extracellular traps might play an important role. We are assessing the role of this risk factor in blot clot formation to advance our understanding of this disease. We expect this will improve our ability to identify the dogs most at risk and enable us to treat them more effectively.
Eligibility: Any dog seen at the Cornell University Hospital for Animals diagnosed with primary IMHA who is larger than 5kg (11 pounds), who has not received any prior immunosuppressive therapy other than steroids, has not had prior heparin treatment, and has not had steroids (like prednisone) in the preceding 72 hours.
Compensation: There is no direct compensation for your participation in this study, but all of the additional testing is free of charge. Your dog's participation may help guide therapies for future patients with IMHA.
Owner Responsibilities: Your dog will have a small amount of extra blood collected when the initial blood work is done. Your dog will be treated with standard of care therapies for IMHA.
Sponsorship: This study is funded by the Gray Lady Foundation
Principal Investigator: Robert Goggs, BVSc, DACVECC, DECVECC, PhD, MRCVS
Contact/Schedule an Appointment: Please contact the internal medicine service, the emergency service, or the clinical trials coordinator at 607.253.3060, or email email@example.com. Your referring veterinarian may also contact the hospital to refer your pet.